Botulism in a pregnant intravenous drug abuser

Anaesthetics, Royal Infirmary of Edinburgh, Edinburgh, UK.
Anaesthesia (Impact Factor: 3.85). 02/2006; 61(1):57-60. DOI: 10.1111/j.1365-2044.2005.04434.x
Source: PubMed

ABSTRACT A case of botulism is reported in a heroin-abusing parturient who initially presented with lethargy and slurred speech. The diagnostic difficulty, complications, intensive care and anaesthetic management of this case are discussed, with particular reference to the pregnancy and the effects of both botulism and its empirical treatment on the fetus. A short review is provided of a condition that has seen a marked increase in its incidence since 2000.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Dermatologists are frequently faced with questions about the safety of commonly prescribed topical and systemic medications during pregnancy and lactation from women of childbearing age who are pregnant, considering pregnancy, or breastfeeding. Safety data, particularly regarding medications that are unique to dermatology, can be difficult to locate and are not consolidated in a single reference guide for clinicians. Parts I and II of this continuing medical education article provide a capsule summary of key points for the most commonly prescribed dermatologic medications to facilitate patient medication risk counseling in pregnancy. A summary table details safety classification data for 3 primary international classification systems: the US Food and Drug Administration, the Swedish Catalogue of Approved Drugs, and the Australian Drug Evaluation Committee. In addition, this table includes an alternative pregnancy classification system developed by a consortium of active members of teratology societies in the US and Europe detailed in Drugs during Pregnancy and Lactation: Treatment Options and Risk Assessment and a safety classification system developed for breastfeeding mothers detailed in Medications and Mother's Milk.
    Journal of the American Academy of Dermatology 03/2014; 70(3):401.e1–401.e14. DOI:10.1016/j.jaad.2013.09.010 · 5.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Attempted suicides and poisonings in pregnancy are a challenge for health care professionals because of the unknown effects of the toxic agent and the antidote therapy on the unborn. In case of intoxication, the malformation risk is often overestimated. In contrast, pertinent data show that the risk is not very high as long as the drug is not known as a teratogen and the mother's health is not substantially impaired. This applies to suicide attempts with acetaminophen, iron-containing products, and multidrug overdoses with psychopharmaceuticals as well as snake and spider bites and the ingestion of poisonous mushrooms. It is of utmost importance that the pregnant patient receives the same detoxification and supportive therapy following pertinent guidelines as a non-pregnant patient. The fetus should be followed-up by ultrasound with special focus on its vital parameters, movement pattern, and normal growth and organ differentiation. As long as the maternal health status is not substantially impaired, there is no indication to discuss elective termination of pregnancy "for toxicological reasons".
    02/2012; 107(2):118-22.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 17-year-old female was treated with botulinum toxin (botulinum toxin type A, Allergan) for a left convergent squint. She returned 1 week after her second injection and informed us that she found out she was pregnant 3 days after the second injection. After a long worrying 9 months, her pregnancy fortunately proceeded to term with no adverse effect on both mother and baby. A literature review reassuringly suggests that it is a relatively safe treatment with no adverse effects on the expectant mother or the fetus. Up to 300 units of botulinum toxin have been used at various stages of pregnancy without adverse effects.
    Strabismus 06/2010; 18(2):65-6. DOI:10.3109/09273971003793930